Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma

British Journal of Cancer

Volumn 111, Issue 10, 2014, Pages 1909-1916

  Suttle, A B ^a   Ball, H A ^b   Molimard, M ^c   Hutson, T E ^d   Carpenter, C ^a,b   Rajagopalan, D ^b   Lin, Y ^b   Swann, S ^b   Amado, R ^b   Pandite, L ^a  

^a Salix a Division of Valeant Pharmaceuticals North America LLC   (United States)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

blood pressure; pazopanib; progression free survival; renal cell carcinoma; trough concentration

Indexed keywords

ALANINE AMINOTRANSFERASE; PAZOPANIB; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE; TUMOR MARKER; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2, HUMAN;

ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CORRELATIONAL STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG SAFETY; DYSGEUSIA; ELEVATED BLOOD PRESSURE; FEMALE; HAIR DISEASE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMATITIS; TREATMENT RESPONSE; VOLUME OF DISTRIBUTION AT STEADY-STATE; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD PRESSURE; CANCER STAGING; CARCINOMA, RENAL CELL; FOLLOW UP; KIDNEY NEOPLASMS; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TISSUE DISTRIBUTION;

ANGIOGENESIS INHIBITORS; BLOOD PRESSURE; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; FOLLOW-UP STUDIES; HUMANS; KIDNEY NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONAMIDES; SURVIVAL RATE; TISSUE DISTRIBUTION; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84922481730     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.503     Document Type: Article

References (35)

1. Australian Government Department of Health and Ageing (2010) Drugs designated as orphan drugs: Pazopanib (PATORMA). http://www.tga. gov.au/industry/pm-orphan-drugs.htm
2. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26(11): 1810-1816
3. Cacheux W, Boisserie T, Staudacher L, Vignaux O, Dousset B, Soubrane O, Terris B, Mateus C, Chaussade S, Goldwasser F (2008) Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. Ann Oncol 19(9): 1659-1661
4. Deng Y, Sychterz C, Suttle AB, Dar MM, Bershas D, Negash K, Qian Y, Chen EP, Gorycki PD, Ho MY (2013) Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica 43(5): 443-453
5. Deprimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, Michaelson MD, Motzer RJ (2007) Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 5: 32
6. Eechoute K, Sparreboom A, Burger H, Franke RM, Schiavon G, Verweij J, Loos WJ, Wiemer EA, Mathijssen RH (2011) Drug transporters and imatinib treatment: implications for clinical practice. Clin Cancer Res 17(3): 406-415
7. Emmons G, Rowland M (2010) Pharmacokinetic considerations as to when to use dried blood spot sampling. Bioanalysis 2(11): 1791-1796
8. European Medicines Agency (2010) Votrient (pazopanib) authorisation details. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001141/human-med-001337.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124&jsenabled=true
9. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24(1): 25-35
10. Haouala A, Zanolari B, Rochat B, Montemurro M, Zaman K, Duchosal MA, Ris HB, Leyvraz S, Widmer N, Decosterd LA (2009) Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 877(22): 1982-1996
11. Harris PA, Boloor A, Cheung M, Kumar R, Crosby RM, Davis-Ward RG, Epperly AH, Hinkle KW, Hunter 3rd RN, Johnson JH, Knick VB, Laudeman CP, Luttrell DK, Mook RA, Nolte RT, Rudolph SK, Szewczyk JR, Truesdale AT, Veal JM, Wang L, Stafford JA (2008) Discovery of 5-[[4-[(2, 3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-m ethyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem 51(15): 4632-4640
12. Heath EI, Chiorean EG, Sweeney CJ, Hodge JP, Lager JJ, Forman K, Malburg L, Arumugham T, Dar MM, Suttle AB, Gainer SD, LoRusso P (2010) A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors. Clin Pharmacol Ther 88(6): 818-823
13. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ (2010) Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 66(2): 357-371
14. Hurwitz H, Douglas PS, Middleton JP, Sledge GW, Johnson DH, Reardon DA, Chen D, Rosen O (2010) Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV). J Clin Oncol 28(15s): abstr 3039
15. Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, Hodge JP, Merkle EM, Pandite L (2009) Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 15(12): 4220-4227
16. Hutson TE, Davis ID, Machiels JP, De Souza PL, Rottey S, Hong BF, Epstein RJ, Baker KL, McCann L, Crofts T, Pandite L, Figlin RA (2010) Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 28(3): 475-480
17. Instituto De Salud Publica De Chile (2010) Votrient coated tablets [product registration]. http://200.68.11.21/RegistrosISP/fiFichaProducto. asp?RegistroISP=F-18018/10
18. Janvier A, Nadeau S, Baribeau J, Perreault T (2005) Role of vascular endothelial growth factor receptor 1 and vascular endothelial growth factor receptor 2 in the vasodilator response to vascular endothelial growth factor in the neonatal piglet lung. Crit Care Med 33(4): 860-866
19. Kidney Cancer Canada (2010) Votrient (pazopanib) approved by Health Canada for the treatment of renal cell carcinoma. http://www.kidneycancercanada. org/main.php?p=600&lan=1
20. Klumpen HJ, Samer CF, Mathijssen RH, Schellens JH, Gurney H (2011) Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treat Rev 37(4): 251-260
21. Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC, Hopper TM, Miller CG, Harrington LE, Onori JA, Mullin RJ, Gilmer TM, Truesdale AT, Epperly AH, Boloor A, Stafford JA, Luttrell DK, Cheung M (2007) Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 6(7): 2012-2021
22. Li B, Ogasawara AK, Yang R, Wei W, He GW, Zioncheck TF, Bunting S, De Vos AM, Jin H (2002) KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF. Hypertension 39(6): 1095-1100
23. Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B, Shalinsky DR, Hu-Lowe DD, McDonald DM (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116(10): 2610-2621
24. Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding G, Agarwal N, Thompson JA, Cella D, Bello A, Korytowsky B, Yuan J, Valota O, Martell B, Hariharan S, Figlin RA (2012) Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 30(12): 1371-1377
25. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24(1): 16-24
26. Pretorius E, Klinker H, Rosenkranz B (2011) The role of therapeutic drug monitoring in the management of patients with human immunodeficiency virus infection. Ther Drug Monit 33(3): 265-274
27. Rini BI (2010) Biomarkers: hypertension following anti-angiogenesis therapy. Clin Adv Hematol Oncol 8(6): 415-416
28. Roodhart JM, Langenberg MH, Witteveen E, Voest EE (2008) The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol 3(2): 132-143
29. Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, Cascinu S (2009) Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 20(2): 227-230
30. Sonpavde G, Hutson TE, Sternberg CN (2008) Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert Opin Investig Drugs 17(2): 253-261
31. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28(6): 1061-1068
32. Tan AR, Gibbon DG, Stein MN, Lindquist D, Edenfield JW, Martin JC, Gregory C, Suttle AB, Tada H, Botbyl J, Stephenson JJ (2013) Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. Cancer Chemother Pharmacol 71(6): 1635-1643
33. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3): 205-216
34. U.S. Department of Health and Human Services Food & Drug Administration (2009) Pazopanib [approval notice] (http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm187509.htm).
35. Wang Y, Chia YL, Nedelman J, Schran H, Mahon FX, Molimard M (2009) A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times. Ther Drug Monit 31(5): 579-584